Risankizumab for severe psoriasis: a case of successful retreatment without induction after 15 months of discontinuation

Ital J Dermatol Venerol. 2024 Apr;159(2):199-200. doi: 10.23736/S2784-8671.23.07691-0.

Authors

Edoardo Mortato¹, Silvia Baratta¹, Riccardo Viola¹, Anna P DE Caro¹, Francesco Loconsole²

Affiliations

¹ Section of Dermatology and Venereology, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy.
² Section of Dermatology and Venereology, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy - franciscus59@gmail.com.

PMID: 38650500
DOI: 10.23736/S2784-8671.23.07691-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal* / therapeutic use
Dermatologic Agents / therapeutic use
Female
Humans
Male
Middle Aged
Psoriasis* / drug therapy
Retreatment
Severity of Illness Index

Substances

risankizumab
Antibodies, Monoclonal
Dermatologic Agents